According to the Zhitong Finance and Economics App, Sinopharm-B (02257) rose more than 25% during trading hours. As of press time, it had risen 17.32% to HKD 5.08 with a turnover of HKD 40.5272 million.

On the news front, Sinopharm announced that Phase I clinical trial of STP122G, a GalNAc RNAi therapeutic agent for anticoagulant therapy, was successfully completed for the second sequence, and interim data was released.

It is reported that this therapeutic product is a novel anticoagulation therapy targeting eleven indicators. The safety data showed that there was no dose-limiting toxicity or serious adverse events, and dose-dependent target silencing activity was observed. Thus, this clinical study will proceed to the next dose group in the next sequence.